Alphamab Oncology (FRA:3NK)

Alphamab Oncology Statistics

Total Valuation

FRA:3NK has a market cap or net worth of EUR 1.12 billion. The enterprise value is 952.63 million.

Market Cap	1.12B
Enterprise Value	952.63M

Important Dates

The last earnings date was Friday, November 28, 2025.

Earnings Date	Nov 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	969.16M
Shares Outstanding	n/a
Shares Change (YoY)	+3.37%
Shares Change (QoQ)	-2.06%
Owned by Insiders (%)	50.09%
Owned by Institutions (%)	4.04%
Float	483.73M

Valuation Ratios

The trailing PE ratio is 40.42.

PE Ratio	40.42
Forward PE	n/a
PS Ratio	11.97
PB Ratio	5.07
P/TBV Ratio	5.07
P/FCF Ratio	43.25
P/OCF Ratio	36.69
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 30.34, with an EV/FCF ratio of 36.83.

EV / Earnings	34.43
EV / Sales	10.01
EV / EBITDA	30.34
EV / EBIT	41.85
EV / FCF	36.83

Financial Position

The company has a current ratio of 4.98, with a Debt / Equity ratio of 0.15.

Current Ratio	4.98
Quick Ratio	4.75
Debt / Equity	0.15
Debt / EBITDA	1.05
Debt / FCF	1.26
Interest Coverage	22.64

Financial Efficiency

Return on equity (ROE) is 13.37% and return on invested capital (ROIC) is 5.76%.

Return on Equity (ROE)	13.37%
Return on Assets (ROA)	5.22%
Return on Invested Capital (ROIC)	5.76%
Return on Capital Employed (ROCE)	9.45%
Revenue Per Employee	193,017
Profits Per Employee	57,175
Employee Count	420
Asset Turnover	0.35
Inventory Turnover	0.83

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +137.81% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+137.81%
50-Day Moving Average	1.31
200-Day Moving Average	0.98
Relative Strength Index (RSI)	48.74
Average Volume (20 Days)	65

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:3NK had revenue of EUR 93.42 million and earned 27.67 million in profits. Earnings per share was 0.03.

Revenue	93.42M
Gross Profit	86.20M
Operating Income	22.35M
Pretax Income	27.67M
Net Income	27.67M
EBITDA	29.93M
EBIT	22.35M
Earnings Per Share (EPS)	0.03

Balance Sheet

The company has 195.50 million in cash and 32.51 million in debt, giving a net cash position of 163.00 million.

Cash & Cash Equivalents	195.50M
Total Debt	32.51M
Net Cash	163.00M
Net Cash Per Share	n/a
Equity (Book Value)	220.49M
Book Value Per Share	0.23
Working Capital	174.31M

Cash Flow

In the last 12 months, operating cash flow was 30.49 million and capital expenditures -4.62 million, giving a free cash flow of 25.87 million.

Operating Cash Flow	30.49M
Capital Expenditures	-4.62M
Free Cash Flow	25.87M
FCF Per Share	n/a

Margins

Gross margin is 92.27%, with operating and profit margins of 23.93% and 29.62%.

Gross Margin	92.27%
Operating Margin	23.93%
Pretax Margin	29.62%
Profit Margin	29.62%
EBITDA Margin	32.04%
EBIT Margin	23.93%
FCF Margin	27.69%

Dividends & Yields

FRA:3NK does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.37%
Shareholder Yield	-3.37%
Earnings Yield	2.47%
FCF Yield	2.31%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:3NK has an Altman Z-Score of 4.94 and a Piotroski F-Score of 7.

Altman Z-Score	4.94
Piotroski F-Score	7